Cardiovascular Revascularization Medicine
Volume 7, Issue 4 , Pages 234-236 , October 2006

Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure

  • Andrew E. Ajani

      Affiliations

    • Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia
    • National Health Medical Research Council, Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
    • Corresponding Author InformationCorresponding author. Department of Cardiology, Royal Melbourne Hospital, Grattan Street, Parkville, 3050, Australia. Tel.: +61 3 9347 0499; fax: +61 3 9347 6760.
    • ,
  • Thomas H. Marwick

      Affiliations

    • University of Queensland Department of Medicine, Princess Alexandra Hospital, Brisbane, Australia
    • ,
  • Henry Krum

      Affiliations

    • National Health Medical Research Council, Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

Received 6 July 2006 ,Accepted 6 July 2006.

References 

  1. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, López-Sendón J, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109:494–499
  2. Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, et al. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J. 2003;145(1):73–79
  3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717
  4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321
  5. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46(3):425–431
  6. Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long-term evaluation. Am J Hypertens. 1999;12(7):665–672
  7. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–1390
  8. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352(25):2581–2588
  9. Cannon CP, Weintraub WS, Demopoulos LA, et al., TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)—Thrombolysis in Myocardial Infarction 18 Investigators  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344(25):1879–1887
  10. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Fast revascularisation during instability in coronary artery disease. Lancet. 2000;356(9223):9–16
  11. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543–551

PII: S1553-8389(06)00185-0

doi: 10.1016/j.carrev.2006.07.002

Cardiovascular Revascularization Medicine
Volume 7, Issue 4 , Pages 234-236 , October 2006

Article Tools